Similarly, the prolonged treatment with the VOCC blocker nimodipine ameliorated age-related memory impairment in rats [62], and isradipine attenuated β-amyloid oligomer toxicity by reducing Cav1.2 expression in vitro and inhibiting Ca2+ influx [63], supporting the feasibility of a therapeutic approach with dihydropyridines in AD patients (reviewed in [64]). The gene discussed is CACNA1C; the disease is Alzheimer disease.